Attovia filed for an initial public offering, positioning the company for public-market funding behind IL-31-targeting immunology assets aimed at severe itching conditions. The listing ambition follows momentum from other recent biotech IPOs and signals that investors continue to fund specialized immunology franchises. In parallel, the IPO window remains active with Braveheart filing to fund phase 3 development tied to a Cytokinetics rival, extending the pattern of clinical-stage assets raising cash via Nasdaq listings. Together, the filings highlight a market dynamic where later-stage readiness and clear clinical pathways are supporting renewed public-company formation. For the sector, these moves matter because IPO proceeds increasingly function as direct catalysts for phase 3 starts rather than only bridge financing.